Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Laure Thouvenin"'
Autor:
Laure Thouvenin, Mélinda Charrier, Sophie Clement, Yann Christinat, Jean-Christophe Tille, Mauro Frigeri, Krisztian Homicsko, Olivier Michielin, Alexandre Bodmer, Pierre O. Chappuis, Thomas A. McKee, Petros Tsantoulis
Publikováno v:
Gynecologic Oncology Reports, Vol 37, Iss , Pp 100787- (2021)
Epithelial ovarian cancer (EOC) is usually diagnosed at an advanced stage and significantly contributes to cancer mortality in women. Despite multimodal treatment associating chemotherapy and surgery, most patients ultimately progress and require pal
Externí odkaz:
https://doaj.org/article/bba19669ae314c2babf356bc5665ae51
Publikováno v:
Therapeutic Advances in Drug Safety, Vol 12 (2021)
Background: Along with the increasing use of immune checkpoint inhibitors comes a surge in immune-related toxicity. Here, we review the currently available data regarding neurological immune adverse events, and more specifically aseptic meningitis an
Externí odkaz:
https://doaj.org/article/89040514d0bc41dcb316338dca6d8811
Autor:
Marc Blondon, Alexandre Bodmer, Laure Thouvenin, Thomas Lecompte, Marc Righini, Pierre Fontana, Alessandro Casini
Publikováno v:
Blood Advances. 6:2884-2892
Tamoxifen and aromatase inhibitors (AIs) are potent antitumoral agents against breast cancer. Tamoxifen increases the risk of venous thromboembolism (VTE), but the influence of AIs on the risk of VTE remains unclear. To inform clinical decisions, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::159590f99383fb4bab8bd8bc8337cd72
https://doi.org/10.1182/bloodadvances.2021006623
https://doi.org/10.1182/bloodadvances.2021006623
Autor:
Laure Thouvenin, Alex Friedlaender
Publikováno v:
Revue Médicale Suisse. 16:1074-1078
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f672673f51a39c5aacee591582ae1ec1
https://doi.org/10.53738/revmed.2020.16.695.1074
https://doi.org/10.53738/revmed.2020.16.695.1074
Autor:
Sophie Clément, Pierre O. Chappuis, Alexandre Bodmer, Krisztian Homicsko, Yann Christinat, Melinda Charrier, Olivier Michielin, Petros Tsantoulis, Daniele Frisone, Thomas Alexander Mckee, Laure Thouvenin
Publikováno v:
Cancer biology & therapy, vol. 21, no. 3, pp. 197-202
Cancer Biology and Therapy, Vol. 21, No 3 (2020) pp. 197-202
Cancer Biology and Therapy, Vol. 21, No 3 (2020) pp. 197-202
Alterations of the Retinoblastoma (Rb) pathway are frequent in ovarian cancer, typically resulting from CDKN2A down-regulation, CCNE1 amplification, CCND1/2 amplification, and RB1 loss. However, bi-allelic CDKN2A mutation or homozygous deletion is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::352c882e2c41b9625dab34c1f829ff27
https://doi.org/10.1080/15384047.2019.1685291
https://doi.org/10.1080/15384047.2019.1685291
Autor:
Laure Thouvenin, Noémie Lang
Publikováno v:
Revue Médicale Suisse. 15:1022-1026
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bacaaa8c971d4cd08544927206811dc7
https://doi.org/10.53738/revmed.2019.15.651.1022
https://doi.org/10.53738/revmed.2019.15.651.1022
Autor:
Laure, Thouvenin, Alex, Friedlaender
Publikováno v:
Revue medicale suisse. 16(695)
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related mortality worldwide. It most often develops in cirrhosis, the etiology varying based on regional risk factors. Multidisciplinary treatment is the cornerstone of the mana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::393c6e242a7ab3dbc2a8500cf86c2b64
https://pubmed.ncbi.nlm.nih.gov/32462834
https://pubmed.ncbi.nlm.nih.gov/32462834
Autor:
Mauro Frigeri, Alexandre Bodmer, Krisztian Homicsko, Jean-Christophe Tille, Olivier Michielin, Thomas Alexander Mckee, Yann Christinat, Petros Tsantoulis, Laure Thouvenin, Sophie Clément, Pierre O. Chappuis, Melinda Charrier
Publikováno v:
Gynecologic Oncology Reports
Gynecologic Oncology Reports, Vol 37, Iss, Pp 100787-(2021)
Gynecologic oncology reports, vol. 37, pp. 100787
Gynecologic Oncology Reports, Vol. 37 (2021) P. 100787
Gynecologic Oncology Reports, Vol 37, Iss, Pp 100787-(2021)
Gynecologic oncology reports, vol. 37, pp. 100787
Gynecologic Oncology Reports, Vol. 37 (2021) P. 100787
Highlights • Trastuzumab monotherapy has limited efficacy in ovarian cancer. • The combination of trastuzumab and pertuzumab has not been studied adequately. • An ERBB2-amplified ovarian carcinoma had a durable response to this combination. •
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c295064b33afba194517ef22e0972280
https://doi.org/10.1016/j.gore.2021.100787
https://doi.org/10.1016/j.gore.2021.100787
Autor:
Daniele, Frisone, Melinda, Charrier, Sophie, Clement, Yann, Christinat, Laure, Thouvenin, Krisztian, Homicsko, Olivier, Michielin, Alexandre, Bodmer, Pierre O, Chappuis, Thomas A, McKee, Petros, Tsantoulis
Publikováno v:
Cancer Biology & Therapy
Alterations of the Retinoblastoma (Rb) pathway are frequent in ovarian cancer, typically resulting from CDKN2A down-regulation, CCNE1 amplification, CCND1/2 amplification, and RB1 loss. However, bi-allelic CDKN2A mutation or homozygous deletion is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::55f252a2da5798695f6662492f9a52ae
https://pubmed.ncbi.nlm.nih.gov/31709901
https://pubmed.ncbi.nlm.nih.gov/31709901
Autor:
Laure, Thouvenin, Noémie, Lang
Publikováno v:
Revue medicale suisse. 15(651)
Monoclonal plasma cell gammopathies (MPCG) describe several forms of abnormal plasma cell proliferation. Their prevalence increases with age. Initially asymptomatic, MPCG can evolve differently and they can tend towards more advanced stages, sometime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d3a1a8d9d7b29b9208115c66c3ef45b3
https://pubmed.ncbi.nlm.nih.gov/31091036
https://pubmed.ncbi.nlm.nih.gov/31091036